^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr del(17p)

    Related tests:
    3d
    ASSURE: Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov)
    P3, N=552, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    16d
    Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation. (PubMed, Sci Transl Med)
    Together, our work identified genetic events linked to the initiation and malignant transformation of MM along the B cell lineage. These findings form the foundation for identifying potential therapeutic strategies for patients with RRMM by targeting MICs and their driving oncogenes.
    Journal
    |
    CD24 (CD24 Molecule) • IRF4 (Interferon regulatory factor 4) • SPI1 (Spi-1 Proto-Oncogene)
    |
    Chr del(17p)
    25d
    Extrachromosomal circular DNA of multiple myeloma. (PubMed, J Cancer)
    We performed a Circle-seq analysis of MM and investigated the heterogeneity of EccDNA. Analysis of data from clinical studies and basic experiments revealed that the gene carried on EccDNA most likely contributed to the increased tolerance of bortezomib in MM with del(17p).
    Journal
    |
    ANXA5 (Annexin A5)
    |
    Chr del(17p)
    |
    bortezomib
    2ms
    Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients. (PubMed, Clin Lymphoma Myeloma Leuk)
    in real world, more than one third of MM patients do not have baseline FISH data. Nevertheless, cytogenetics and ECOG PS can be used for prognostic staging and for tailoring therapy.
    Journal • Real-world evidence • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    Chr del(17p) • Chr t(11;14)
    3ms
    The Prognostic Value of Amplification of the MYCC and MYCN Oncogenes in Russian Patients with Medulloblastoma. (PubMed, Diseases)
    Amplification of the MYC gene is a predictor of poor overall survival to therapy and a high risk of metastatic relapse. This allows us to more accurately stratify patients into risk groups in order to determine the intensity and duration of therapy.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • RARA (Retinoic Acid Receptor Alpha)
    |
    Chr del(17p)
    4ms
    T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    4ms
    NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation. (PubMed, Blood Neoplasia)
    Human acute myeloid leukemia (AML) cell lines with partial loss of NAMPT and primary samples from patients with -7 AML demonstrated heightened sensitivity to the NAMPT inhibitor KPT-9274 compared to control samples...These findings indicate that NAMPT heterozygosity is a therapeutic vulnerability in high-risk myeloid malignancies with -7/del(7q) and recommend NAMPT levels as a biomarker for NAMPT inhibitor sensitivity. This study also establishes a data-driven framework for identifying collateral lethal genes in cancers with recurrent chromosomal deletions.
    Journal • PARP Biomarker
    |
    TP53 (Tumor protein P53) • NAMPT (Nicotinamide Phosphoribosyltransferase)
    |
    Chr del(17p)
    |
    padnarsertib (KPT-9274)
    4ms
    Daratumumab, Carfilzomib, Pomalidomide, and Dexamethasone for High Risk Newly Diagnosed Multiple My (ChiCTR2500104311)
    P4, N=40, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • Chr del(17p)
    |
    Darzalex (daratumumab) • carfilzomib • pomalidomide
    5ms
    MIR4726EccDNA drives bortezomib resistance in multiple myeloma by enhancing MIR4726-5p/NXF1/NKIRAS2 axis dependent autophagy. (PubMed, Cell Commun Signal)
    In summary, our findings indicate that artificially synthesized MIR4726EccDNA is functional in cells and that MIR4726EccDNA enhances tumor progression and partially mediates drug resistance by enhancing MIR4726-5p/NXF1/NKIRAS2 axis dependent autophagy.
    Journal
    |
    NXF1 (Nuclear RNA Export Factor 1) • NKIRAS2 (NFKB Inhibitor Interacting Ras Like 2)
    |
    Chr del(17p)
    |
    bortezomib
    7ms
    Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=89, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Completed | Trial completion date: Dec 2025 --> May 2024 | Trial primary completion date: Sep 2025 --> May 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Chr del(17p) • Chr del(11q) • MLL rearrangement
    |
    cyclophosphamide • sirolimus • fludarabine IV
    8ms
    High Tumor Mutation Burden (TMB) and a Novel Somatic Mutation in the TREX1 Gene in a Patient with Aggressive and Refractory High-Grade B-Cell Lymphoma: A Case Report. (PubMed, Int J Mol Sci)
    An inactivating somatic mutation in the TREX1 gene (p.T49fs) has not been previously described in patients with non-Hodgkin lymphomas. Additionally, our analysis uncovered a key cancer hallmark: tumor genomic instability, manifested as a high tumor mutational burden, which likely contributed to the aggressive disease course.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BCL2 (B-cell CLL/lymphoma 2) • B2M (Beta-2-microglobulin) • CREBBP (CREB binding protein) • STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT6 (Signal transducer and activator of transcription 6)
    |
    TP53 mutation • TMB-H • Chr del(17p)
    8ms
    Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024
    Trial completion • Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Chr del(17p)
    |
    bortezomib • sirolimus • melphalan • fludarabine IV